Ultra-fast Antimicrobial Susceptibility Test for diagnosing antimicrobial resistance to provide personalized antibiotic treatments

Informations projet

Nanosynex

N° de convention de subvention: 828621

DOI

10.3030/828621

Projet clôturé

Date de signature de la CE 23 Juillet 2018

Date de début 1 Juin 2018

Date de fin 30 Novembre 2018

Financé au titre de

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Coût total

€ 71 429,00

Contribution de l’UE

€ 50 000,00

Coordonné par

NANOSYNEX LTD
Israel

Periodic Reporting for period 1 - Nanosynex (Ultra-fast Antimicrobial Susceptibility Test for diagnosing antimicrobial resistance to provide personalized antibiotic treatments)

Période du rapport: 2018-06-01 au 2018-11-30

Résumé du contexte et des objectifs généraux du projet

The current implementation of antimicrobial stewardship programs in hospitals has not been enough to mitigate the overuse and misuse of antibiotics. Current AST (Antimicrobial Susceptibility Testing) diagnostic methods are highly accurate but take too long (a few days) to obtain results. As a result, doctors have to resort to inaccurate empirical antibiotic therapy to treat their patients prior to the results from the AST. To solve this problem, Nanosynex is developing an ultra-fast microfluidic diagnostic technology that delivers results in only 4 hours, at low cost. Nanosynex will revolutionize the AST workflow by providing health-care systems with the ability to administer targeted antibiotics on the same day the patient enters the hospital without further compounding the issue of AMR, and significantly reduce the large economic burden associated.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

During the project period, Nanosynex continued improving the already excellent performance of its existing prototype, including an in-house study on clinical samples, which showed promising validation data. The company conducted in-depth market analysis and risk assessment by gathering information on competitors and using existing marketing tools (e.g. SWOT analysis) in order to refine its strategy and business model. This analysis allowed the company to identify key potential partners, better define the initial targeted market and geographical segmentation, therefore contributing to reduce business risks.

During the project period, Nanosynex attended several specialized conferences (e.g. MEDICA fair in Germany), increasing its network by getting additional engagement from stakeholders and potential customers who showed high excitement and willingness to strongly supported the project as shown by the additional recommendations and letters of support we received.

The company performed a full operational, technological and financial analysis to refine its strategic business focus and development of milestones throughout and after this project completion. This analysis, together with the excellent validation data obtained during the SME H2020 phase 1 period, contributed to Nanosynex successful fundraising of ~€867K ($1M) in seed investment from a private family office specialized in Life Sciences and frontier tech, that can follow up for next round of investment, and to securing an additional prestigious innovation grant from the Israel Innovation Authority, to support the next steps to commercialisation.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

Nanosynex led an in-depth effort of gathering of competitive intelligence data and confirmed that its product is the only one that can deliver ultra-fast phenotypic AST in only four hours (from clinical isolates and potentially directly from patients’ urine sample), with high sensitivity, so it is well ahead of the current state of the art. Indeed, Nanosynex is addressing a critical need of clinical practitioners and microbiology labs, inside and outside hospitals, for faster AST to be carried as routine in their daily activities. The AST sector has been lacking significant innovation for the past 50 years and Nanosynex is addressing this gap. Nanosynex unique technology is supported by strong clinical validation data: over twenty experiments were successfully performed by the Nanosynex R&D team during the feasibility study and showed excellent results. Socioeconomically, main impacts are related to: • Medical management • Use of resources • Costs • Labour intensity • Patients’ claims.

Team and success